Grifols sets the week with analyst focus, shares under technical pressure
Published on 06/23/2026 at 18:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 16:45.
Grifols (ES0171996087) opens this Tuesday with a clear view on its Nasdaq-listed shares. Technical analysis points to a sell signal around 7.28 US dollars after Monday’s US close, while the risk profile is mapped against pharmaceuticals peers.
What the technicals show today
On Nasdaq, Grifols shares last closed at 7.28 US dollars on 2026-06-22, with data showing the price sandwiched between resistance at 7.89 dollars and support at 6.96 dollars.Technical overview on TradingKey According to this technical snapshot, the stock records 0 buy signals and 4 sell signals across common indicators, while moving averages from 5 to 200 days register 0 buy and 6 sell signals.
The same analysis assigns Grifols a current price momentum score of 6.35, ranking it 115th out of 157 companies in the broader pharmaceuticals industry by this metric.TradingKey momentum and signals Based on this framework, the shares are described as suitable for range-bound swing trading within the identified resistance and support band.
Risk profile and peer comparison
Beyond pure chart signals, Grifols’ risk assessment score stands at 7.30 on a 0 to 10 scale in one quantitative model, placing it 38th among 157 tracked pharmaceuticals names for combined volatility, financial and investment risk measures.Risk assessment details on TradingKey This ranking positions the company in the upper tier of its sector by this risk gauge, alongside large international peers such as GSK in Europe.
A separate analysis of risk-adjusted performance shows a five-year Sharpe ratio of -0.7788 for Grifols, compared with a peer average of 0.4920, indicating historically weaker compensation for volatility versus comparable healthcare names.Benzinga profile on Grifols In this context, the stock’s quantitative profile remains cautious relative to established large-cap pharmaceuticals groups.
All news and analysis on the Grifols shares
Further background, regulatory filings and price data on Grifols can be found in the dedicated topic section and on the company’s investor relations pages.
The business behind the listing
Grifols generates most of its revenue in the biopharma segment, where it manufactures plasma-derived therapies for conditions such as hemophilia, immune deficiencies and certain neurological diseases.Company segment breakdown on Benzinga Additional divisions cover diagnostic testing equipment and reagents for blood screening, as well as bio supplies and contract manufacturing services for other healthcare companies.
Where the stock trades today
The Grifols shares (ES0171996087) last traded on Nasdaq on 2026-06-22 at 7.28 US dollars at 16:00 ET, matching the closing price used in recent technical and risk assessments.
Key data on the Grifols shares
- Company: Grifols S.A.
- ISIN: ES0171996087
- WKN: 927891
- Ticker: GRFS
- Trading venue: NASDAQ
- Price (as of 2026-06-22, 16:00): 7.28 USD
- Market cap: 6.33 billion USD (as of 2026-06-22)
- Sector / industry: Healthcare / Pharmaceuticals
- Index membership: Not a member of S&P 500 or NASDAQ-100
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any financial instrument.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
